IP Verse

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer - EP3305285B1

PatentPatent Analysis

EP3305285

ARAGON PHARMACEUTICALS
Application Number
EP17187458A
Filing Date
Sep 23, 2013
Status
Revoked
Aug 22, 2024
Grant Date
Sep 2, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3226841B1
EP3226843B1
EP3533792B1

Bibliography

The patent EP3305285B1 was granted to Aragon Pharmaceuticals on Sep 2, 2020 following the initial filing on Sep 23, 2013 under the application number EP17187458A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 2, 2021ADMISSIBLE
SYNTHONJun 2, 2021ADMISSIBLE
TEVA PHARMACEUTICALSJun 2, 2021ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents